Manus Neurodynamica secures £2.6m funding to advance NeuroMotor Pen
Manus Neurodynamica, which develops and markets merchandise and applied sciences for neuromotor evaluation, has closed a £2.6 million funding spherical to assist the commercialisation of its NeuroMotor Pen – a medical system to assist prognosis and monitoring of neuromotor issues together with Parkinson’s illness.
Current traders supported the £2.6 million funding spherical together with the North East Innovation Fund, supported by the European Regional Improvement Fund, and managed by Northstar Ventures co-leading the spherical with Par Fairness with participation from SIS Ventures, Scottish Enterprise and Previous School Capital.
The funding will enable Manus to proceed its launch into the EU pharmacy retail sector, targeted on prevention screening, and international medical markets, serving to to distinguish between Parkinson’s and different motion issues, aiding the affected person pathway and decreasing prices. The funds may also assist the corporate’s utility for US FDA regulatory clearance and progressing its US trials, in addition to additional creating and implementing its US commercialisation technique.
The corporate just lately introduced it has obtained funding from Johnson & Johnson Innovation to additional the utility of the NeuroMotor Pen into immunotherapy. Though funding has been obtained immediately from J&J to undertake a medical trial for the detection of neuromotor antagonistic results following CAR T-cell remedy, the funding spherical will assist optimising the configuration of the NeuroMotor Pen for this indication. Moreover, it can assist growth of the pen in different neurological circumstances, comparable to Alzheimer’s illness.
Dr Rutger Zietsma, CEO of Manus, stated: “I’d prefer to thank Manus’ current traders for supporting the Firm’s commercialisation programme of our distinctive NeuroMotor Pen, constructing on earlier assist we obtained in 2021. This 12 months is about to be an thrilling one, with partnerships already secured, and we really imagine our non-invasive and CE-marked product can have a huge effect on sufferers and sort out the unmet want for a fast, cheap system that may detect neurological circumstances, notably given the ageing international inhabitants.”
Alastair Moore, senior funding supervisor at Par Fairness added: “Manus is quickly establishing itself as a go-to diagnostic for neurological circumstances and with funding secured to now receive US regulatory clearance off the again of attaining FDA breakthrough standing, the subsequent 18 months promise to be transformational. The NeuroMotor Pen’s capability to quickly and non-invasively decide whether or not a person requires additional care has potential to ship huge effectivity good points for well being techniques whereas enabling the person to have readability on the which means of their signs inside minutes.”